pharma · Breast Cancer · Multiple Sclerosis (MS)
HOFFMANN-LA ROCHE
Hoffmann-La Roche
Hoffmann-La Roche is a pharma organization headquartered in Basel, CH. Primary therapeutic focus areas include Breast Cancer, Multiple Sclerosis (MS), Spinal Muscular Atrophy (SMA), Non-Small Cell Lung Cancer, Solid Tumo
Mississauga, Ontario L5N 5M8, CA HQ
10 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- Mississauga, Ontario L5N 5M8, CA
- Employees
- 10
- Programs
- 286
- Drugs
- 212
- Patents
- 0
First-in-Human Study of RO7812653
Phase 1 · other · Early Symptomatic Alzheimer’s Disease (eAD), (Mild Cognitive Impairment due to AD, or probable AD dementia)
First-in-Human Study of RO7812653 for Early Symptomatic Alzheimer’s Disease (eAD), (Mild Cognitive Impairment due to AD, or probable AD dementia) is a Phase 1 program (other) at Hoffmann-La Roche with 1 ClinicalTrials.gov record(s).
Internal code BP45770
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Hoffmann-La Roche
- Phase
- Phase 1
- Modality
- other
- Indication
- Early Symptomatic Alzheimer’s Disease (eAD), (Mild Cognitive Impairment due to AD, or probable AD dementia)
- Status
- active
- Trials
- 1